TTrialPathMatch Me to Trials
← Back to trials
RecruitingInfiltrationShoulder Osteoarthritis

Comparison of the Analgesic Effect of 2 Shoulder Infiltrations

Eligible age

20+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

For patients suffering of osteoarthritis, only analgesic treatments such as anti-inflammatory drugs and cortisone infiltrations provide significant but temporary relief of their pain. The objective is to compare the analgesic effect of 2 infiltrations: Cingal (sodium hyaluronate and triamcinolone) versus cortisone (triamcinolone). It is anticipated that the Cingal infiltration will have a greater analgesic effect than a simple cortisone infiltration in patients with moderate to severe osteoarthritis of the shoulder. Method: * Randomized controlled trial * Monocentric * Randomization will be done using sealed envelopes

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

You may qualify if…

  • A clinical examination that confirms the radiological diagnosis of moderate to severe primary shoulder osteoarthritis, stage II and above, according to the Samilson-Prieto classification.
  • Patients aged between 20 and 90 years.
  • A patient with bilateral shoulder osteoarthritis will choose the side of the infiltration, only one side can be chosen to participate in the study.
  • The patient must have a clinical pain threshold of a minimum of 4/10 on the visual analogue scale.
  • The patient must have the cognitive ability to read and fill out the questionnaires.
  • The patient must be able to read and understand French or English

You may not qualify if…

  • Presence of a transfixing rotator cuff tear assessed on MRI.
  • No previous shoulder reconstruction surgery.
  • Pregnant woman.
  • A patient who has received a cortisone infiltration within 6 months prior to the start of the study.
  • A patient who has received a platelet-rich plasma or a hyaluronic acid infiltration within 12 months prior to the start of the study.
  • Diagnosis of avascular necrosis.
  • Disease affecting the studied joint (systemic inflammatory disease, history of septic arthritis, osteonecrosis, etc.)
  • Suspicion or presence of active local infectious process.

Source: ClinicalTrials.gov · NCT05408065 · last updated 2024-02-12